What does DR Dan Shelly bring to the mix as the new Vice...

What does DR Dan Shelly bring to the mix as the new Vice President of Business Development and Alliances for Prescient Therapeutics? (appointed Nov 2020)

Director Global Business Development and Strategic Partnerships, Essential Medicines at PATH
Full-time from Oct 2019 – Nov 2020
Responsible for leading initiatives to seek out new and novel technologies for developing world diseases (vaccines, drugs, devices and diagnostics) and to assist PATH in generating new/novel funding mechanisms. PATH's mission is to advance health equity through innovation and partnerships with the goal of improving health outcomes for more than 1.4 billion people in low-resource settings by creating and advancing quality health solutions.

Director Business Development at Albumedix / Jan 2016 - Nov 2020
Director for Business Development at Albumedix.
Business Development representative for both the team leading the Clinical Development of the Albumedix drug development pipeline and for the team leading Externalization of Research and Development.

Albumedix develops albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery.
Their products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies worldwide.
Held responsibility for business development around the out-licensing of the Albumedix Veltis technology for improving pharmacokinetics and delivery of APIs bound to modified albumin.
Was instrumental in the development of an expanded vision around the use of albumin not only for half-life extension but possibly for use in vaccines, cancer immunomodulation and novel routes of delivery.
Specifically:
Dr. Shelly drove significant licensing deals, was a key member of the R&D Externalization team and was the commercial lead on the Clinical Development team responsible for Albumedix’s clinical portfolio.

Director Business Development at Novozymes Biopharma / Jun 2011 – Jan 2016

Novozymes Biopharma is a part of Novozymes A/S, the world leader in bioinnovation.
With over 25 years of leadership in biomanufacturing and process development, Novozymes offers animal-free, regulatory-compliant, dedicated and proven solutions to help you optimize your manufacturing process, drug formulation and drug delivery.
Dan was Director of Strategic Accounts with responsibility for recombinant and sequence modified Albumin products for formulation, half-life extension, cancer immunomodulation and oral delivery.
His previous experience with cell culture production of recombinant proteins and vaccines along with an in depth understanding of the drug development process facilitated working closely with prospective clients and find Novozymes Biopharma solutions to their challenges and needs.

Director, Business Development at Meridian Life Science, Feb 2004 – Jun 2011
Director of Marketing and Business Development for Meridian Life Science, Inc. from 2004 to June 2011 and was responsible for contract Biologics manufacturing and business development.
In 2007, was given responsibility for the contract cGMP Biologics manufacturing and grew the business by double digits annually with ~49% growth projection for 2011.
The pipeline of projects and contracts generated justified two facility expansions; one in 2009 and again in 2011. Responsibilities included marketing the Biologics business focusing on scientific communication via publications, posters, collaborative product development agreements, and thought leader relationships. Another responsibility was in licensing and development of a recombinant human Parvovirus B19 VLP Vaccine including writing the global exclusive license, conducting marketing assessments, valuation, clinical development protocols, investigator brochures, IND sections, FDA meetings and the final clinical study manuscript.
A partner for this program was found just prior to my departure for Novozymes Biopharma.

Key strategic positional appointment moving forward in my opinion

not intended as financial advice - dyor